Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ ...

Cardiovascular disease still claims more lives than any other illness, and many adults living with obesity or type 2 diabetes carry a heavy risk of heart attack and stroke. Two medications, ...

Researchers conducted the UP-TAINED study to assess the effectiveness and safety of upadacitinib for over 2 years, with patients with moderate to severe AD receiving either 15 mg or 30 mg once daily.

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S. Although biomarker testing in early-stage non-small cell ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Faricimab offers extended dosing intervals for DME, reducing injection frequency compared to traditional anti-VEGF therapies. The study showed improvements in CST and visual acuity in both ...

Please provide your email address to receive an email when new articles are posted on . In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion ...